At what enterprise value was VITAL DIAGNOSTICS acquired in 2013?

You can find the full valuation details of VITAL DIAGNOSTICS on mynth capital. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.8x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of VITAL DIAGNOSTICS when it was acquired by ELITECH GROUP?

The exact EV/EBITDA multiple for VITAL DIAGNOSTICS is available on mynth capital. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.8x. Join our community for free to access full valuation data and industry trends.

When was VITAL DIAGNOSTICS acquired by ELITECH GROUP?

VITAL DIAGNOSTICS was acquired by ELITECH GROUP in 2013.

What was the revenue of VITAL DIAGNOSTICS at the time of the deal?

The revenue of VITAL DIAGNOSTICS at the time of the deal is estimated to be in the range of 25M - 50M USD. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of VITAL DIAGNOSTICS during the acquisition?

VITAL DIAGNOSTICS's EBITDA is estimated to be in the range of 0M - 5M USD. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the VITAL DIAGNOSTICS acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the VITAL DIAGNOSTICS deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://capitalfinance.lesechos.fr/deals/build-up/elitech-group-rachete-vital-diagnostics-103998

← DATABASE

Home Database Healthcare & PharmaVITAL DIAGNOSTICS

01/2013

VITAL DIAGNOSTICS acquired by ELITECH GROUP

UNITED STATES Life Sciences / Medical Devices / Diagnostic Equipment REV 25M - 50M USD

Context

Instead of a simple territorial expansion, this cross-border maneuver acts as a catalyst for ELITech Group’s "300 Million Euro" roadmap, fundamentally rebalancing its geographic revenue split. By capturing Vital Diagnostics, the group secures a turnkey infrastructure for the US physician office laboratory market while gaining an immediate foothold in the Australian and New Zealand clinical sectors. The strategic rationale centers on the industrial synergy between the target’s benchtop analyzer expertise and the group's established chemical reagent pipeline.

VITAL DIAGNOSTICS, which reported an EBITDA margin of LOGIN in 2012, is valued in this transaction at an EV/EBITDA multiple of LOGIN, a level to compare with the average currently observed in the Healthcare & Pharma sector (14.8x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Vital Diagnostics operates as a premier technology organization dedicated to the engineering and distribution of clinical chemistry analyzers and specialized reagents. The entity’s business model is centered on a proprietary framework of benchtop diagnostic systems specifically designed for the physician office laboratory (POL), small-to-medium-sized hospitals, and specialized clinics. Its value proposition is anchored in technical operational depth, providing integrated hardware and chemical assay solutions that facilitate decentralized medical testing. Strategically, the firm focuses on the "near-patient" testing niche, ensuring that diagnostic results are both rapid and accurate within primary care settings. By maintaining a specialized focus on clinical chemistry and hematology, the organization ensures a mission-critical role in the structural efficiency of laboratory workflows across North America and Australasia. The entity prioritizes manufacturing quality and technical support to facilitate the structural advancement of community-based healthcare diagnostics.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (USD)

Year

Rev

EBITDA

EBIT

2012

2011

Similar deals in Healthcare & Pharma

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
10/2013	ARDIAN	LABORATOIRES ANIOS	FRANCE	Life Sciences	Air Liquide has entered into exclusive negotiations to sell its 66% majority stake in Laboratoires Anios to a consortium comprised of Ardian and the founding Letartre brothers, Bertrand and Thierry. This transaction represents a strategic spin-off for Air Liquide, allowing the industrial gas giant to refocus its hygiene activities exclusively on its German subsidiary, Schülke & Mayr
07/2013	CHARTERHOUSE	DOC GENERICI	ITALY	Life Sciences	Charterhouse acquired 100% of DOC Generici from a consortium of three pharmaceutical companies: Apotex (Canada), Chiesi Farmaceutici (Italy), and Zambon (Italy). The deal was structured as a Management Buyout, backing the incumbent CEO
06/2013	EURAZEO	PÉTERS SURGICAL	FRANCE	Life Sciences	The acquisition of Péters Surgical by Eurazeo PME is a strategic move that reflects the investment firm's commitment to supporting the growth and development of medium-sized enterprises in the healthcare sector
06/2013	BC PARTNERS	ANTELLIQ	FRANCE	Life Sciences	BC Partners has successfully finalized the acquisition of a majority stake in the share capital of the target from a UK-based investment trust. This strategic transaction represents a secondary leveraged buyout designed to accelerate the organization’s shift toward electronic identification and digital monitoring technologies
08/2012	BC PARTNERS	AENOVA GROUP	GERMANY	Life Sciences	BC Partners have signed a definitive agreement to acquire a majority stake in the Aenova Group from the European private equity firm Bridgepoint. This secondary LBO marks the end of Bridgepoint’s ownership period, which began in 2005, during which Aenova was transformed into one of Europe’s leading CDMOs
05/2011	AZULIS CAPITAL / BNP PARIBAS DEVELOPPEMENT / GALIA	LAGARRIGUE	FRANCE	Life Sciences	Following an initial OBO three years prior (where debt was fully repaid), Lagarrigue completed a majority LBO led by Azulis Capital. The consortium, including BNP Paribas Developpement, Galia Gestion, and historical investor iXO PE, acquired approximately 80% of the capital
09/2010	SPARRING CAPITAL	IMV TECHNOLOGIES	FRANCE	Life Sciences	OFI Private Equity Capital announced the sale of its majority stake in IMV Technologies to Pragma Capital (Renamed Sparring Capital). OFI PE retains a minority stake of 11% by reinvesting EUR5 million alongside the management team led
09/2009	THE CARLYLE GROUP	MARLE GROUP	FRANCE	Life Sciences	The Carlyle Group has acquired an 80% majority stake in Marle S.A. The company's President, Bernard Marle, along with his family, has reinvested to retain a 20% stake. This Primary LBO is designed to support the company's growth in a market expanding at 8% annually
04/2007	ASTORG	ETHYPHARM	FRANCE	Life Sciences	Astorg Partners has entered into a definitive agreement to acquire a 60% majority stake in Ethypharm. The transaction follows a competitive sale process that included both industrial players and other private equity funds
01/2006	EDMOND DE ROTHSCHILD CAPITAL PARTNERS	ACTEON	FRANCE	Life Sciences	Acteon (formerly Satelec-Pierre Rolland), a Mérignac-based medical-dental equipment and consumables manufacturer, has finalized a LBO transaction. Led by Edmond de Rothschild Capital Partners (ERCP) through the special purpose vehicle Financière Noé, the private equity sponsor acquires a 51% controlling interest, while the management team rolls over its equity to retain a 49% stake

REFERENCES

Revenue range: 25M - 50M USD

EBITDA range: 0M - 5M USD

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of VITAL DIAGNOSTICS by ELITECH GROUP are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).